Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2008-02-14
2009-12-15
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
C514S012200
Reexamination Certificate
active
07632503
ABSTRACT:
A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
REFERENCES:
patent: 5164370 (1992-11-01), Ballard et al.
patent: 6329501 (2001-12-01), Smith
patent: 6509443 (2003-01-01), Dubaquie et al.
patent: 2002/0137023 (2002-09-01), Smith et al.
patent: 2002/0164702 (2002-11-01), Valenzuela et al.
patent: WO 90/15142 (1990-12-01), None
patent: WO 96/08274 (1996-03-01), None
patent: WO 97/21811 (1997-06-01), None
patent: WO 98/50432 (1998-11-01), None
patent: WO 98/53804 (1998-12-01), None
patent: WO 99/10494 (1999-03-01), None
patent: WO 03/070195 (2003-08-01), None
Glass, D. et al., ( 1997), Current Opinion Neurpbiology, vol. 7, No. 3, pp. 379-384.
Glass, D. et al., (1996),Agrin acts via a musk recptor complex, Cell, May 17, vol. 85, No. 4 pp. 513-523.
Liyanage, Y. et al., (2002), Muscle and Nerve, vol. 25 No. 1, Jan., pp. 4-16.
Dubaquite et al.,(1998), Biochemistry, vol. 38, May 18, pp. 6386-6396.
Shin, S-U et al., (1994), Journal of Biological Chemistry, vol. 269, No. 7, Feb. 18, pp. 4979-4985.
Shin, S-U et al., (1990), PNAS, vol. 87, No. 14, pp. 5322-5326.
Water et al., (1999), Angiostatin binds to smooth muscle cells in the coronary . . . , Arteriosclerosis Thrombosis & Vascular Biology, vol. 19, pp. 2041-2048.
Francis et al., (1995), CuZn Superoxide Dismutase (SOD-1): Tetanus Toxin Fragment C Hybrid . . . , J. Biol. Chem., vol. 270, pp. 15434-15442.
Halin et al., (2002), Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature, Nature Biotechnology vol. 20, pp. 264-269.
Ohno et al., (1995) Cell targeting for gene delivery . . . , Biochemical and molecular medicine, vol. 56, pp. 172-175.
Samoylova et al., (1998), Elucidation of muscle-binding peptides by phage display screen, Muscle and Nerve, vol. 22, pp. 460-466.
Donalies et al., (1991) Expression of m-cadherin, a member of the caderin multigene family . . . , Proc. Natl. Acad. Sci. USA, vol. 88, pp. 8024-8028.
Chappuis-Flament et al., (2001), Multiple cadherin extracellular repeats mediate homophilic bindings and adhesion, J. Cell Bio, vol. 154, pp. 231-243.
Leal, A. M.O. et al., (2002), Endocrinology, vol. 143, No. 3, pp. 964-969.
Hill, J. J. et el., (2002), J. of Biol. Chem, vol. 277, No. 43, pp. 40735-40741.
Wolfman, N. M. et al, (2003), PNAS, vol. 100, No. 26, pp. 15842-154846.
Kaufman. U. et al., (1999), Journal of Cell Science, vol. 112, pp. 55-67.
Glass David J.
Latres Esther
Stitt Trevor
Dang Ian
Gregg, Esq. Valeta
Landsman Robert
Regeneron Pharmaceuticals Inc.
Yokoyama, Esq. Izumi
LandOfFree
Method of treating a muscle-related condition with modified... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating a muscle-related condition with modified..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating a muscle-related condition with modified... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090350